

Hillel Tobias, M.D., Ph.D., F.A.C.P.
Concorde Medical Group
232 East 30th Street
New York, NY 10016
(212) 889-5544

CURRENT PROFESSIONAL APPOINTMENTS AND ACTIVITIES:

- Medical Director, Senior Transplant Physician and Consultant Hepatologist, Organ Transplantation Service, New York University Medical Center
- Hepatologist, Division of Gastroenterology, Department of Internal Medicine, New York University Medical Center- Clinical Professor of Medicine, New York University Medical School
- Attending Physician, New York University Medical Center and Bellevue Hospital Center
- CEO & Medical Director – MaryLea Johnson Richards Research Institute, Inc.
- Consultant Hepatologist, New York City Liver Transplant Consortium
- Member, UNOS Regional Transplantation Review Board
- Member, Scientific Advisory Board, American Liver Foundation

CURRENT AND RECENT RESEARCH:

- Phase 4 Protocol RFHE3001- A multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the efficacy, safety and tolerability of Rifaximin 550mg BID for 6 months in preventing hepatic encephalopathy, Salix Pharmaceuticals, Inc., October 2005-October 2007.
- Phase 4 NYC Solid Protocol-Open-Label Pilot Study of the Safety and Tolerability of High Dosage of Interferon Alfacon-1 (Infergen, C1FN) plus Ribavirin Administered Daily for 48 Weeks in Hepatitis C Genotype 1 Infected Patients Who Are Nonresponders to Previous Pegylated Interferon Alfa plus Ribavirin Therapy, Heny C. Bodenheimer, Jr., M.D. August 2004-Dec. 2008.
- Phase 4 Protocol ML 17756-A prospective, Randomized, Open-label Study Evaluating the Viral Kinetics & Pharmacokinetics of Pegasys plus Copegus and PEG- Intron plus Rebetol in Interferon naïve Patients with Chronic Hepatitis C, Hoffman LaRoche Pharmaceuticals, March 2004-November 2005.
- Phase 4 WIN-R Study, Protocol P02314-Comparison of Peg Interferon alfa-2b Plus Ribavirin Given as a fixed Dose or on a Weight Optimized Basis for Treatment of Chronic, Schering-Plough, closed July 2005.

EDUCATION;

A.B. - Columbia College, 1956

M.D. - Washington University, St. Louis, Missouri, 1960

Ph.D. - University of London, 1968

**Internship: New York University (Third Division) - Medicine at
Bellevue Hospital, New York, New York, 1960-61**

**Residency: New York University (Third Division) - Medicine at
Bellevue Hospital, New York, New York, 1961-63**

**Post-Doctoral: N.I.H. Research Fellow and Ph.D. student at University of London
1963-65, with Professor Dame Sheila Sherlock, Medical Unit, Royal Free
Hospital Medical School, London England.**

N.I.H. Special Fellow in Gastroenterology, Mt. Sinai Hospital, New York 1965-67

CERTIFICATIONS:

Board Certified, American Board of Internal Medicine, 1967

Board Certified, American Board of Internal Medicine, Subspecialty Gastroenterology, 1979

Fellowship, American College of Physicians, 1975

CAQ Transplant Hepatology 2007

PROFESSIONAL SOCIETIES:

American Society of Transplant Physicians
American Association for the Study of Liver Disease
American Gastroenterological Association
New York Academy of Gastroenterology
New York Gastroenterological Society
American Society of Internal Medicine
New York County Medical Society
New York State Medical Society

PUBLICATIONS:

1. Ethanol Induced Alterations in Lipid Metabolism, Tobias, H. and Dawson, A.M., in **Therapeutic Agents and the Liver**, N. McIntyre and S. Sherlock, eds., Blackwell, 1965, pp. 121-130.
2. The liver and postheparin plasma lipolytic activity in dog and man. Condon, R.E., Tobias, H., and Dawson, A.M. **J.Clin. Invest.**, 44:869, 1965.
3. Free fatty acid mobilization and plasma triglyceride clearance in alcoholic hyperlipemia. Tobias, H., and Dawson, A.M., **Gastroenterology** 50:393, 1966.
4. Lymphocyte stimulation and chronic liver disease. Tobias, H., Safran, A., and Schaffner, F., **Gastroenterology**, 52:1098, 1967.
5. Lymphocyte stimulation and chronic liver disease. Tobias, H., Safran, A., and Schaffner, F., **Lancet**, 1:193, 1967.
6. Coronary artery disease in primary biliary cirrhosis, Kaufman, L., Tobias, H., and Schaffner, F., **Gastroenterology**, 52:1098, 1967.
7. **Alcoholic Hyperlipidemia**, Tobias, H., Ph.D., Thesis, University of London, 1968 (260 pp).
8. Hepatic dysfunction in heroin addicts – Alcohol vs. viral etiology, Stimmel, B., Vernace, S., and Tobias, H., **Gastroenterology** 60:754, 1971. (Also **JAMA**, 222:811, 1972).
9. Hepatic function in patients on Methadone Maintenance Therapy, Stimmel, B., Vernace, S., and Tobias, H., **Proceedings of the Fourth National Methadone Conference**. 1972
10. Hepatotoxicity of Long-Term Methotrexate Therapy for Psoriasis. Tobias, H., and Auerbach, R. **Arch. Internal Med.** 132:391, 1973
11. Total Body perfusion in the treatment of hepatic coma secondary to fulminant Hepatitis. Tobias, H., and Isom, W., **Gastroenterology** 64:157, 1973.
12. Crystalloid hepatic structures in patients with cutaneous Porphyria. Tobias, H., Waldo, E. et al. **Gastroenterology** 64:198, 1973.
13. Needle-like cytoplasmic inclusions in the liver in Porphyria Cutanea Tarda, Waldo, E., and Tobias, H. **Arch. Path.**, 96:368, 1973.
14. The relationship of biological false positive reactions in Heroin dependency to liver function. Stimmel, B., and Tobias, H. **American J. Gastroenterology**, 61:195, 1974
15. The Surgical Patient with Liver Disease. Tobias, H., **Surgical Medicine**, Vol. L, No. 6, 1974.
16. Oxacillin associated Hepatitis, Klein, I., and Tobias, H., **Amer. J. Gastroenterology**, 65:546, 1976.
17. Carcinoma of the gallbladder: A diagnosis aided by endoscopic retrograde and percutaneous hepatic cholangiography. Musher, D.R., Madayag, M.A. and Tobias, H. **Amer. J. Gastro.**, 66:498, 1977.
18. Primary sclerosing cholangitis, Ackert, J., and Tobias, H., **Amer. J. Gastro.**, 68:498, 1977.
19. Liver involvement in the syndrome of Mixed Cryoglobulinemia. Levo, Y., Gorevic, P., H., Tobias, H., and Franklin, E., **Ann. Intern. Med.**, 87:287, 1977.
20. Essential Mixed Cryoglobulinemia: Another connective tissue disorder associated with Hepatitis B Virus infection. Tobias, H., Levo, Y., and Franklin, E., **Gastroenterology** 72:No.1, 1977.
21. Asanguinous hypothermic Total Body Washout (TBW). Tobias, H., Ackert, J., and Isom, W., **Gastroenterology**, 72:No. 5, 1977.
22. The changing spectrum of sporadic Hepatitis in increased risk groups in New York. Dieterich, D, and Tobias, H., **Hepatology**, 2:739, 1982.
23. Longterm effects of Etretinate on the liver in Psoriasis. Camuto, P., Newman, M., Auerbach, R., Tobias, H. and Feiner, H., **Lab Invest**. 1987.
24. Reversibility of Methotrexate-associated Hepatic Fibrosis. Camuto, P., Newman, M., Auerbach, R., Tobias, H. and Feiner, H., **Lab. Invest**. 1987.
25. The importance of serial liver biopsies in the Methotrexate treatment of Psoriasis. Newman, M., Auerbach, R., Feiner, H., Tobias, H., **Hepatology** 7:1088, 1987.

26. The role of liver biopsies in Psoriatic patients receiving long-term Methotrexate treatment, Newman, M., Auerbach, R., Feiner, H., Holzman, R., Shupack, J., Migdal, P., Culubret, M., Camuto, P., Tobias, H. **Arch. Dermatology**, 125, Sept. 1989.
27. Effectiveness of high dose/long term Alfa Interferon Therapy in Chronic Hepatitis C. Tobias, H., Sherman, A., Michaud, J., Teperman, L., et al. **Gastroenterology** 106:999, 1994.
28. Change in platelet-associated antibodies with Orthotopic Liver Transplantation. Goldenber, A., Teperman, L., Tobias, H., et al **Hepatology** 20:351, 1994.
29. Elevations of platelet-associated antibodies during Orthotopic Liver Transplant rejections. Teperman, L., Goldenberg, A., Tobias, H., et al **Hepatology** 10:406, 1994.
30. MRI detection of macroregenerative (dysplastic) nodules and small hepatocellular carcinomas in Cirrhotic livers. Thiese, N., Krinsky, G., Mizrachi, H., Rofsky, N., Goldenberg, A., Tobias, H., Diflo, T., Weinreb, J., Teperman, L. **Hepatology** 22:185, 1995.
31. Hepatobiliary Tuberculosis. In: **Tuberculosis**. Rom, WN., Garay, SM., Tobias, H., Sherman, A., (eds) Little Brown. Boston pp 599-608, 1996.
32. Drug Hepatitis. Chronic Hepatitis In: **Medicine For Practicing Physician**. Tobias, H., Sherman, A., Hurst, JW. (ed) Appelton and Lange; pp1686-1689, 1698-1702, 1996.
33. Ischemic Hepatitis. Cirrhosis In: **Medicine For Practicing Physician**. Sherman, A., Tobias, H., Hurst, JW. (ed) Appleton and Lange; ppl690-1696, 1996.
34. Immunohistochemical staining of Hepatitis C Antigen with Monoclonal Antibody Tordji-22 compares favorably with Polymerase Chain Reaction. Brody, R., Tobias, H., Thiese, N.,
35. Diltiazem is a safe drug in transplant patients on Prograf and does not affect Prograf Levels. Teperman, L., Diflo, T., Tobias, H. et al. **Hepatology** 24:180, 1996.
36. Induction immunotherapy in Liver Transplantation with Mycophenolate Mofetil and Steroids. John, D., Morgan, G., Tobias, H. et al. **Hepatology** 24:529, 1996.
37. Waiting time for liver transplantation increases the risk of incidental hepatocellular carcinomas found in explants. Teperman, L., Mizrachi, H., Tobias, H. et al. **Hepatology** 24:587, 1996.
38. Chemoembolization of hepatocellular carcinoma induces capsule formation. Mizrachi, H., Tobias, H. et al. **Hepatology** 24:588, 1996.
39. Tacrolimus dose is age dependent. Teperman, L., Tobias, H., Morgan, G., et al. **Hepatology**, 1998.
40. Chemoembolization and orthoptic liver transplantation for hepatocellular cancer. Goldenberg, A., Tobias, H., Teperman, L., et al. **Hepatology** 1998.
41. High dose interferon treatment of Hepatitis C. Tobias, H., Cohen, J., Sherman, A., et al. **Hepatology**, 1998.
42. Recurrent Hepatitis B prophylaxis following liver transplantation . Morgan, G., Tobias, H., Teperman, L., et al. **Proc. Americ. Soc. Transpl. Surg.** Pp205, 1998.
43. Pre-transplant chemoembolization for the treatment of Stage 3 and 4a hepatoma. Morgan, G., Goldenberg, A., Tobias, H., Teperman, L. et al. **Proc. Amer. Soc. Transpl. Surg.** Pp174, 1998.
44. Interferon a-2b and ribavirin in patients with chronic Hepatitis C without sustained response to prior interferon. Legovics, E., Tobias, H., Klion, F., Jakobson, I., et al. **Hepatology** 28:286, 1998.
45. The canals of Hering may represent the primary target of methotrexate hepatic toxicity. Thiese, N., Tobias, H., Papadimitriou, C.S., et al. **Hepatology** 28:603, 1998.

46. Recurrent Hepatitis B: Predictors and prophylaxis following liver transplantation. Morgan, G., Diflo, T., Tobias, H., Teperman, L. et al **Hepatology**, 28:773, 1998.
47. Interferon Alfa-2b and Ribavirin in patients with Resistant Chronic Hepatitis C. Min. A., Tobias, H., Jacobson, I., Klion, F., Bodenheimer, H. et al **Hepatology** 30:192A, 1999.
48. Interferon Alfa-2b and Ribavirin in Treatment-Naïve Patients with Chronic Hepatitis C and Normal ALT levels. Jacobson, I., Lebovics, E., Tobias, H., Klion, F. et al **Hepatology**, 30:459A, 1999.
49. The role of iron overload in human hepatocarcinogenesis in chronic Hepatitis C Cirrhosis. An, H.-J., Teperman, L., Tobias, H., Diflo, T., Morgan, G., John, D., Theise, N. **Hepatology** 32:360-365, 2000.
50. Recipients of right lobe grafts from live donors experience acute rejection rates than recipients of cadaveric whole livers. Mohamed, W., Tobias, H., Devon, J., et al. **Hepatology** 36: 660, 2002.
51. Variations in risk factors for HCV Recurrence after living donor and cadaveric liver transplantation. Teperman, L., Tobias, H., Diflo, T., Morgan, G., Theise, N., et al. **Hepatology** 36:654, 2002.
52. Pegylated Interferon Alfa-2b plus Ribavirin in patients with Chronic Hepatitis C A trial in prior nonresponders to interferon monotherapy or combination therapy and in combination therapy relapsers. Jacobson, I., Russo, M., Tobias, H., et al. **Hepatology** 36:358, 2002.
53. Recipients are rarely denied right lobe living donor liver transplantation solely because of donor biliary anomalies. Morgan, G., Lavelle, M., Krinsky, G., Diflo, T., Tobias, H., Teperman, L., et al. **Hepatology** 36:675, 2002.
54. The canals of Hering may represent a target of methotrexate hepatic toxicity. Theise, N., Tobias, H. et al. **American Journal of Clinical Pathology**, 2003.
55. Treatment Algorithm for the management of Chronic Hepatitis B Virus Infection In the United States, Keefe, E.B., Tobias, H. **Clinical Gastro & Hepatitis** 2:90-106 (2004).
56. Hepatitis B: Advances in Clinical Management and Outcome, Tobias, H. **Presentation in Focus** November 1, 2004
57. Hepatitis B: Awards in Clinical Management & Outcome, Tobias, H. , **Presentation in Focus**, February 2005.
58. Medical Need for Anesthesiologist-Administered Propofol, Tobias, H., Kefalides, P., **AGA Perspectives** , February/March 2005, Volume 1, Issue 1
59. Screening for Chronic Hepatitis B Among Asian/Pacific Islander Populations, **Morbidity and Mortality Weekly Report**, Pollack, H., Tobias, H. 55:18; 505-507 (2006)
60. A Treatment Algorithm for the Management of Chronic Hepatitis B Virus Infection in the U.S. Keefe, E.; Dieterich, D.; Han, S.; Jacobson, I., Martin, P., Schiff, E., Tobias, H., Wright, T. **Clinical Gastroenterology and Hepatology** (2006) in press.
61. Diffusion-Weighted MRI for the Quantification of Liver Fibrosis: Preliminary Experience, Taouli, B., Tolia, A., Losada, M., Babb, J., Chan, E., Bannan, M., Tobias, H. **Department of Radiology, Pathology, Pharmacology and Medicine-Division of Hepatology, NYU Medical Center.**
62. Needle Orientation During Transjugular Liver Biopsy, McCann, J., Tobias, H., Martinez, M., John, D., Clark, T., New York University School of Medicine, New York, NY